The U.S. Supreme Court has agreed to hear a case challenging the common pharmaceutical industry practice of paying generic drug manufacturers to drop their patent challenges, which critics say hurts consumers by keeping prices high.

FORBES: Supreme Court Takes Generic `Pay To Delay' Case

The practice involves pharmaceutical manufacturers paying generic manufacturers to delay the release of a generic drug in anticipation of the patent cliff.

FORBES: Data War Reaches The Supreme Court

Though generic firms and new companies tend to outsource more than the big drug companies, the practice is growing there, too.

FORBES: Ghost cars, ghost brands